Immunology Learning Goals Spring 2011
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Immunology New Orleans, LA Toll Free 888.355.4191 Toll Free Fax 888.355.4192 Krogerspecialtypharmacy.Com
Immunology New Orleans, LA toll free 888.355.4191 toll free fax 888.355.4192 krogerspecialtypharmacy.com Need By Date: _________________________________________________ Ship To: Patient Office Fax Copy: Rx Card Front/Back Clinical Notes Medical Card Front/Back Patient Information Prescriber Information Patient Name Prescriber Name Address Address City State Zip City State Zip Main Phone Alternate Phone Phone Fax Social Security # Contact Person Date of Birth Male Female DEA # NPI # License # Clinical Information Diagnosis: J45.40 Moderate Asthma J45.50 Severe Asthma L20.9 Atopic Dermatitis L50.1 Chronic Idiopathic Urticaria (CIU) Eosinophil Levels J33 Chronic Rhinosinusitis with Nasal Polyposis Other: ________________________________ Dx Code: ___________ Drug Allergies Concomitant Therapies: Short-acting Beta Agonist Long-acting Beta Agonist Antihistamines Decongestants Immunotherapy Inhaled Corticosteroid Leukotriene Modifiers Oral Steroids Nasal Steroids Other: _____________________________________________________________ Please List Therapies Weight kg lbs Date Weight Obtained Lab Results: History of positive skin OR RAST test to a perennial aeroallergen Pretreatment Serum lgE Level: ______________________________________ IU per mL Test Date: _________ / ________ / ________ MD Specialty: Allergist Dermatologist ENT Pediatrician Primary Care Prescription Type: Naïve/New Start Restart Continued Therapy Pulmonologist Other: _________________________________________ Last Injection Date: _________ / ________ -
The Ligands for Human Igg and Their Effector Functions
antibodies Review The Ligands for Human IgG and Their Effector Functions Steven W. de Taeye 1,2,*, Theo Rispens 1 and Gestur Vidarsson 2 1 Sanquin Research, Dept Immunopathology and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Netherlands; [email protected] 2 Sanquin Research, Dept Experimental Immunohematology and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Netherlands; [email protected] * Correspondence: [email protected] Received: 26 March 2019; Accepted: 18 April 2019; Published: 25 April 2019 Abstract: Activation of the humoral immune system is initiated when antibodies recognize an antigen and trigger effector functions through the interaction with Fc engaging molecules. The most abundant immunoglobulin isotype in serum is Immunoglobulin G (IgG), which is involved in many humoral immune responses, strongly interacting with effector molecules. The IgG subclass, allotype, and glycosylation pattern, among other factors, determine the interaction strength of the IgG-Fc domain with these Fc engaging molecules, and thereby the potential strength of their effector potential. The molecules responsible for the effector phase include the classical IgG-Fc receptors (FcγR), the neonatal Fc-receptor (FcRn), the Tripartite motif-containing protein 21 (TRIM21), the first component of the classical complement cascade (C1), and possibly, the Fc-receptor-like receptors (FcRL4/5). Here we provide an overview of the interactions of IgG with effector molecules and discuss how natural variation on the antibody and effector molecule side shapes the biological activities of antibodies. The increasing knowledge on the Fc-mediated effector functions of antibodies drives the development of better therapeutic antibodies for cancer immunotherapy or treatment of autoimmune diseases. -
IFM Innate Immunity Infographic
UNDERSTANDING INNATE IMMUNITY INTRODUCTION The immune system is comprised of two arms that work together to protect the body – the innate and adaptive immune systems. INNATE ADAPTIVE γδ T Cell Dendritic B Cell Cell Macrophage Antibodies Natural Killer Lymphocites Neutrophil T Cell CD4+ CD8+ T Cell T Cell TIME 6 hours 12 hours 1 week INNATE IMMUNITY ADAPTIVE IMMUNITY Innate immunity is the body’s first The adaptive, or acquired, immune line of immunological response system is activated when the innate and reacts quickly to anything that immune system is not able to fully should not be present. address a threat, but responses are slow, taking up to a week to fully respond. Pathogen evades the innate Dendritic immune system T Cell Cell Through antigen Pathogen presentation, the dendritic cell informs T cells of the pathogen, which informs Macrophage B cells B Cell B cells create antibodies against the pathogen Macrophages engulf and destroy Antibodies label invading pathogens pathogens for destruction Scientists estimate innate immunity comprises approximately: The adaptive immune system develops of the immune memory of pathogen exposures, so that 80% system B and T cells can respond quickly to eliminate repeat invaders. IMMUNE SYSTEM AND DISEASE If the immune system consistently under-responds or over-responds, serious diseases can result. CANCER INFLAMMATION Innate system is TOO ACTIVE Innate system NOT ACTIVE ENOUGH Cancers grow and spread when tumor Certain diseases trigger the innate cells evade detection by the immune immune system to unnecessarily system. The innate immune system is respond and cause excessive inflammation. responsible for detecting cancer cells and This type of chronic inflammation is signaling to the adaptive immune system associated with autoimmune and for the destruction of the cancer cells. -
Ch. 43 the Immune System
Ch. 43 The Immune System 1 Essential Questions: How does our immunity arise? How does our immune system work? 2 Overview of immunity: Two kinds of defense: A. innate immunity present at time of birth before exposed to pathogens nonspecific responses, broad in range skin and mucous membranes internal cellular and chemical defenses that get through skin macrophages, phagocytic cells B. acquired immunity (adaptive immunity)develops after exposure to specific microbes, abnormal body cells, foreign substances or toxins highly specific lymphocytes produce antibodies or directly destroy cells 3 Overview of Immune System nonspecific Specific 4 I. Innate immunity Nonspecific defenses A. First line of defense: skin, mucous membranes skin protects against chemical, mechanical, pathogenic, UV light damage mucous membranes line digestive, respiratory, and genitourinary tracts prevent pathogens by trapping in mucus *breaks in skin or mucous membranes = entryway for pathogen 5 secretions of skin also protect against microbes sebaceous and sweat glands keep pH at 35 stomach also secretes HCl (Hepatitis A virus can get past this) produce antimicrobial proteins (lysozyme) ex. in tears http://vrc.belfastinstitute.ac.uk/resources/skin/skin.htm 6 B. Second line of defense internal cellular and chemical defenses (still nonspecific) phagocytes produce antimicrobial proteins and initiate inflammation (helps limit spread of microbes) bind to receptor sites on microbe, then engulfs microbe, which fused with lysosome nitric oxide and poisons in lysosome can poison microbe lysozyme and other enzymes degrade the microbe *some bacteria have capsule that prevents attachment *some bacteria are resistant to lysozyme macrophages 7 Cellular Innate defenses Tolllike receptor (TLR) recognize fragments of molecules characteristic of a set of pathogens [Ex. -
Discussion of Natural Killer Cells and Innate Immunity
Discussion of natural killer cells and innate immunity Theresa L. Whiteside, Ph.D. University of Pittsburgh Cancer Institute Pittsburgh, PA 15213 Myths in tumor immunology • Cancer cells are ignored by the immune system • Immune responses are directed only against “unique” antigens expressed on tumor cells • Tumor-specific T cells alone are sufficient for tumor regression • Tumor are passive targets for anti-tumor responses Tumor/Immune Cells Interactions Tumor cell death C G DC M TUMOR NK Th B Tc Ab Ag Ag/Ab complex NK cells as anti-tumor effectors • LGL, no TCR, express FcγRIII, other activating receptors and KIRs • Spare normal cells but kill a broad range of tumor cells ex vivo by at least two different mechanisms • Produce a number of cytokines (IFN-γ, TNF-α) • Constitutively express IL-2Rβγ and rapidly respond to IL-2 and also to IL-15 and IFNα/β • Regulated by a balance of inhibitory receptors specific for MHC class I antigens and activating signals • NK-DC interactions at sites of inflammation Heterogeneity of human NK cells • Every NK cell expresses at least one KIR that recognizes a self MHC class I molecule • Two functionally distinct subsets: 1) 90% CD56dimCD16bright , highly cytotoxic, abundant KIR expression, few cytokines 2) 10% CD56brightCD16dim/neg, produce cytokines, poorly cytotoxic, low KIR expression Expression of activating and inhibitory receptors on NK cells Interaction with CD56 Interaction with MHC ligands non-MHC ligands KIR CD16 CD2 CD94/NKG2A/B β2 NKp46, 44, 30 CD94/NKG2C/E NK Cell 2B4 NKG2D Lair1 LIR/ILT A -
C3b Catalog Number: A114 Sizes Available
Name: C3b Catalog Number: A114 Sizes Available: 250 µg/vial Concentration: 1.0 mg/mL (see Certificate of Analysis for actual concentration) Form: Liquid Purity: >90% by SDS-PAGE Buffer: 10 mM sodium phosphate, 145 mM NaCl, pH 7.3 Extinction Coeff. A280 nm = 1.03 at 1.0 mg/mL Molecular Weight: 176,000 Da (2 chains) Preservative: None, 0.22 µm filtered Storage: -70oC or below. Avoid freeze/thaw. Source: Normal human serum (shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-1 and HIV-II). Precautions: Use normal precautions for handling human blood products. Origin: Manufactured in the USA. General Description C3b is derived from native C3 upon cleavage and release of C3a. It is prepared by cleavage with the alternative pathway C3 convertase. This is important because only a single bond in C3 is cleaved by the native convertase, while cleavage by other proteases, such as trypsin, results in multiple cleavages at many other sites in the protein. Native human C3b is a glycosylated (~2.8%) polypeptide containing two disulfide-linked chains. C3b is central to the function of all three pathways of complement (Law, S.K.A. and Reid, K.B.M. (1995)). Initiation of each pathway generates proteolytic enzyme complexes (C3 convertases) which are bound to the target surface. These enzymes cleave a peptide bond in C3 releasing the anaphylatoxin C3a and activating C3b. For a brief time (~60 µs) this nascent C3b is capable of reacting with and covalently coupling to hydroxyl groups on the target surface. -
We Work at the Intersection of Immunology and Developmental Biology
Development and Homeostasis of Mucosal Tissues U934/UMR3215 – Genetics and Developmental Biology Pedro Hernández Chef d'équipe [email protected] We work at the intersection of immunology and developmental biology. Our primary goal is to understand how immune responses impact the development, integrity and function of mucosal tissue layers, such as the intestinal epithelium, during homeostasis and upon different types of stress, including infections. To study these questions we exploit the advantages of the zebrafish model such as ex utero and rapid development, transparency, large progeny, and simple genetic manipulation. We combine live imaging, flow cytometry, single-cell transcriptomics, and models inducing mucosal stress, including pathogenic challenges. Our research can be subdivided into three main topics: 1) Protection of intestinal epithelial integrity since early development: Epithelial cells are at the core of intestinal organ function. They are in charge of absorbing nutrients and water, and at the same time constitute a barrier for potential pathogens and harmful molecules. Epithelial cells perform all these functions before full development of the immune system, which promotes epithelial barrier function upon injury. We study how robust epithelial integrity is achieved prior and after maturation of the intestinal immune system, with a focus on the function of mucosal cytokines. 2) Epithelial-leukocyte crosstalk throughout development: Intestines become vastly populated by leukocytes after exposure to external cues from diet and colonization by the microbiota. We have recently reported the existence and diversity of zebrafish innate lymphoid cells (ILCs), a key component of the mucosal immune system recently discovered in mice and humans. ILCs mediate immune responses by secreting cytokines such as IL-22 which safeguards gut epithelial integrity. -
B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells
cells Review B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells Carlo G. Bonasia 1 , Wayel H. Abdulahad 1,2 , Abraham Rutgers 1, Peter Heeringa 2 and Nicolaas A. Bos 1,* 1 Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9713 Groningen, GZ, The Netherlands; [email protected] (C.G.B.); [email protected] (W.H.A.); [email protected] (A.R.) 2 Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 Groningen, GZ, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Autoreactive B cells are key drivers of pathogenic processes in autoimmune diseases by the production of autoantibodies, secretion of cytokines, and presentation of autoantigens to T cells. However, the mechanisms that underlie the development of autoreactive B cells are not well understood. Here, we review recent studies leveraging novel techniques to identify and characterize (auto)antigen-specific B cells. The insights gained from such studies pertaining to the mechanisms involved in the escape of tolerance checkpoints and the activation of autoreactive B cells are discussed. Citation: Bonasia, C.G.; Abdulahad, W.H.; Rutgers, A.; Heeringa, P.; Bos, In addition, we briefly highlight potential therapeutic strategies to target and eliminate autoreactive N.A. B Cell Activation and Escape of B cells in autoimmune diseases. Tolerance Checkpoints: Recent Insights from Studying Autoreactive Keywords: autoimmune diseases; B cells; autoreactive B cells; tolerance B Cells. Cells 2021, 10, 1190. https:// doi.org/10.3390/cells10051190 Academic Editor: Juan Pablo de 1. -
Case of the Anti HIV-1 Antibody, B12
Spectrum of Somatic Hypermutations and Implication on Antibody Function: Case of the anti HIV-1 antibody, b12 Mesfin Mulugeta Gewe A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Roland Strong, Chair Nancy Maizels Jessica A. Hamerman Program Authorized to Offer Degree: Molecular and Cellular Biology i ii ©Copyright 2015 Mesfin Mulugeta Gewe iii University of Washington Abstract Spectrum of Somatic Hypermutations and Implication on Antibody Function: Case of the anti HIV-1 antibody, b12 Mesfin Mulugeta Gewe Chair of the Supervisory Committee: Roland Strong, Full Member Fred Hutchinson Cancer Research Center Sequence diversity, ability to evade immune detection and establishment of human immunodeficiency virus type 1 (HIV-1) latent reservoirs present a formidable challenge to the development of an HIV-1 vaccine. Structure based vaccine design stenciled on infection elicited broadly neutralizing antibodies (bNAbs) is a promising approach, in some measure to circumvent existing challenges. Understanding the antibody maturation process and importance of the high frequency mutations observed in anti-HIV-1 broadly neutralizing antibodies are imperative to the success of structure based vaccine immunogen design. Here we report a biochemical and structural characterization for the affinity maturation of infection elicited neutralizing antibodies IgG1 b12 (b12). We investigated the importance of affinity maturation and mutations accumulated therein in overall antibody function and their potential implications to vaccine development. Using a panel of point iv reversions, we examined relevance of individual amino acid mutations acquired during the affinity maturation process to deduce the role of somatic hypermutation in antibody function. -
Activation Regulates Alternative Pathway Complement Necrotic
Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation This information is current as of September 27, 2021. Wei Xu, Stefan P. Berger, Leendert A. Trouw, Hetty C. de Boer, Nicole Schlagwein, Chantal Mutsaers, Mohamed R. Daha and Cees van Kooten J Immunol 2008; 180:7613-7621; ; doi: 10.4049/jimmunol.180.11.7613 Downloaded from http://www.jimmunol.org/content/180/11/7613 References This article cites 56 articles, 27 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/180/11/7613.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation1,2 Wei Xu,* Stefan P. Berger,* Leendert A. -
Pathway in the Thymus by a CD24-Dependent Autoreactive T
Autoreactive T Cells Escape Clonal Deletion in the Thymus by a CD24-Dependent Pathway This information is current as Joseph W. Carl, Jr., Jin-Qing Liu, Pramod S. Joshi, Hani Y. of September 27, 2021. El-Omrani, Lijie Yin, Xincheng Zheng, Caroline C. Whitacre, Yang Liu and Xue-Feng Bai J Immunol 2008; 181:320-328; ; doi: 10.4049/jimmunol.181.1.320 http://www.jimmunol.org/content/181/1/320 Downloaded from References This article cites 54 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/181/1/320.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Autoreactive T Cells Escape Clonal Deletion in the Thymus by a CD24-Dependent Pathway1 Joseph W. Carl, Jr.,* Jin-Qing Liu,* Pramod S. -
Natural Killer T Cells Are Required for the Development of a Superantigen-Driven T Helper Type 2 Immune Response in Mice
IMMUNOLOGY ORIGINAL ARTICLE Natural killer T cells are required for the development of a superantigen-driven T helper type 2 immune response in mice Auro Nomizo,1 Edilberto Postol,2 Summary Raquel de Alencar,2 Fabı´ola We show, here, that one single injection or weekly injections of staphylo- Cardillo2 and Jose´ Mengel2 coccal enterotoxin B (SEB), starting in 1-day-old newborn mice, induced 1Department of Clinical Analysis, Toxicology a powerful immune response with a T helper type 2 (Th2) pattern, as and Bromatology, Faculty of Pharmaceutical Sciences of Ribeira˜o Preto, University of Sa˜o judged by the isotype and cytokine profile, with the production of large Paulo, Ribeira˜o Preto, and 2Department of amounts of SEB-specific immunoglobulin G1 (IgG1), detectable levels of Immunology, Institute of Biomedical Sciences, SEB-specific IgE and increased production of interleukin-4 by spleen cells. University of Sa˜o Paulo, Sa˜o Paulo, SP, Brazil These protocols also induced an increase in the levels of total IgE in the serum. Memory of SEB was transferred to secondary recipients by using total spleen cells from primed animals. The secondary humoral response in transferred mice was diminished if spleen cells from SEB-treated mice were previously depleted of CD3+ or Vb8+ T cells or NK1.1+ cells. In vivo depletion of NK1.1+ cells in adult mice resulted in a marked reduction in the SEB-specific antibody response in both the primary and secondary doi:10.1111/j.1365-2567.2005.02215.x immune responses. Additionally, purified NK1.1+ T cells were able to per- Received 11 April 2005; revised 23 May 2005; form SEB-specific helper B-cell actions in vitro and in vivo.